Poacher turned gamekeeper

Parvus Therapeutics Inc. is developing a nanoparticle system it believes could offer a comprehensive solution for chronic inflammatory conditions. By transforming T cells targeting self-antigens into Tregs that dampen the immune response, the particles shut down antigen presentation and end autoimmune flares, providing a way to address autoimmunity that doesn't depend on the molecular pathway involved.

The company licensed the technology from the University of Calgary - where CSO and founder Pere Santamaria runs a lab - and plans to begin testing in humans for Type I diabetes, multiple sclerosis (MS) and rheumatoid arthritis (RA) in 2018. ...